Multiplex SLE Biomarker Index for Disease Activity Forecasting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current biomarkers for Systemic Lupus Erythematosus (SLE) have limited utility in forecasting persistent organ damage and clinical disease activity, and existing clinical instruments are labor-intensive and prone to variability, hindering proactive management of the disease.
Innovation Solution
A method involving the assessment of multiple biomarkers, including innate, adaptive, chemokine, soluble TNF superfamily, and autoantibody specificities, to calculate a Lupus Disease Activity Immune Index (LDAII) that characterizes disease activity and progression, using a multiplex assay to detect protein expression levels and correlate them with autoantibody specificities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current biomarkers (ANA specificities) are used to assess SLE disease activity, then disease classification can be achieved, but the ability to forecast persistent organ damage and clinical disease activity is limited
Solution Approach 1:
The patent segments the assessment of SLE disease activity into multiple independent biomarker categories: innate serum/plasma mediators (IL-1a, IL-1β, IL-6, IFN-α, IL-12p70, IL-23p19), adaptive serum/plasma mediators (IL-2, IFN-γ, IL-5, IL-13, IL-17A, IL-21, IL-10, TGF-β), chemokine/adhesion molecules (IL-8/CXCL8, IP-10/CXCL10, MIG/CXCL9, MIP-1α/CCL3, MIP-1β/CCL4, MCP-1/CCL2, MCP-3/CCL7, ICAM-1), soluble TNF superfamily members (TNFRI, TNFRII, TRAIL, TWEAK, CD40L/CD154, BLyS, APRIL), and SLE-associated autoantibody specificities (dsDNA, chromatin, RiboP, Ro/SSA, La/SSB, Sm, SmRNP, RNP). This segmentation allows each biomarker category to contribute specific information about different aspects of disease activity, thereby improving the overall forecasting capability while reducing information loss.
2Measurement precision
If validated clinical disease activity instruments are used, then disease activity can be assessed, but the instruments are labor-intensive and prone to variability
Solution Approach 1:
The patent replaces manual clinical assessment instruments with an automated multiplex assay system that simultaneously measures multiple biomarkers in a single test. This substitution of mechanical/manual assessment with automated biochemical analysis reduces labor intensity and inter-observer variability while maintaining or improving measurement precision through objective quantitative detection of biomarker levels.
Solution Approach 2:
The multiplex assay system performs multiple functions simultaneously: it detects innate mediators, adaptive mediators, chemokines, adhesion molecules, soluble TNF superfamily members, and autoantibodies all in one test. This multi-functionality consolidates what would otherwise require multiple separate clinical instruments and assessments into a single comprehensive platform, reducing overall system complexity while improving measurement precision.
3Productivity
If reactive treatment strategies are used to manage SLE, then clinical symptoms can be treated, but proactive management to prevent organ damage is precluded
Solution Approach 1:
The patent enables preliminary action by identifying biomarker patterns that predict future disease activity and organ damage before clinical manifestations occur. By detecting elevated levels of specific biomarkers (such as IL-6, IFN-α, autoantibodies) in advance, clinicians can initiate protective treatments before damage occurs, transitioning from reactive to proactive disease management and reducing the time delay between disease onset and intervention.
Data Source
AI summary
The present invention includes a method of characterizing disease activity in a systemic lupus erythematosus patient (SEE), comprising: obtaining a dataset associated with a blood, serum, plasma or urine sample from the patient, wherein the dataset comprises data representing the level of one or more biomarkers in the blood, serum, plasma or urine sample from each of (b) to (g); at least one innate serum or plasma mediator biomarker; at least one adaptive serum or plasma mediator; at least one chemokine/adhesion molecule biomarker; at least one soluble TNF superfamily biomarker; the inflammatory mediator biomarker SCF; at least one SLE-associated autoantibody specificity biomarker; and calculating a Lupus Disease Activity Immune.